Global Hereditary Angioedema Therapeutics Market 2018-2022 | Emergence of Innovative Treatment Strategies | Technavio

The global hereditary angioedema therapeutics market 2018-2022 is expected to post a CAGR of close to 9% during the forecast period, according to the latest markey research report by Technavio.

LONDON--(BUSINESS WIRE)-- The global hereditary angioedema therapeutics market 2018-2022 is expected to post a CAGR of close to 9% during the forecast period, according to the latest market research report by Technavio.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180918005944/en/

Technavio has published a new market research report on the global hereditary angioedema therapeutic ...

Technavio has published a new market research report on the global hereditary angioedema therapeutics market for the period 2018-2022. (Graphic: Business Wire)

A key factor driving the growth of the market is the increasing prevalence of hereditary angioedema. The rising cases of hereditary angioedema are increasing the possibility of transmission of the disease to the future generation. Therefore, it is expected that the distribution of the disease and the demand for therapeutics will increase during the coming years, which, in turn, results in the growth of the global hereditary angioedema therapeutics market.

This market research report on the global hereditary angioedema therapeutics market 2018-2022 also provides an analysis of the most important trends expected to impact the market outlook during the forecast period. Technavio classifies an emerging trend as a major factor that has the potential to significantly impact the market and contribute to its growth or decline.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

In this report, Technavio highlights the emergence of innovative treatment strategies as one of the key emerging trends in the global hereditary angioedema therapeutics market:

Global hereditary angioedema therapeutics market: Emergence of innovative treatment strategies

The main challenge of the high cost of treatment can be resolved with the help of self-administration of the therapeutics. Self-administration reduces cost by reducing the frequent visits to hospitals. Several pharmaceutical companies are taking various initiatives to make patients aware of the treatment and procedure.

“For instance, Shire has organized a self-administration training under “The Path to independence” program. This program provides training about the administration of CINRYZE by specialized nurses. This program includes training related to storage, handling, and disrupting of CINRYZE. Such instances help patients to get the disease diagnosed and treated before it gets complex,” says a senior analyst at Technavio.

Global hereditary angioedema therapeutics market: Segmentation analysis

This market research report segments the global hereditary angioedema therapeutics market by product (C1 inhibitors, icatibant, ecallantide, and others) and geographical regions (APAC, EMEA, and the Americas).

The Americas led the market in 2017 with a market share of close to 42%, followed by APAC and EMEA respectively. The region is expected to continue to dominate the market during the forecast period.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Market Landscape

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

Market Sizing

  • Market definition
  • Market size and forecast

Five Forces Analysis

Market Segmentation

Geographical Segmentation

  • Regional comparison
  • Key leading countries

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
www.technavio.com

Source: Technavio Research

Smart Multimedia Gallery

Technavio has published a new market research report on the global hereditary angioedema therapeutics market for the period 2018-2022. (Graphic: Business Wire)

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20180918005944/en

MORE ON THIS TOPIC